N
Nanjing Puguang Biotechnology
A developer of in vitro medical diagnostic systems
About Nanjing Puguang Biotechnology
Nanjing Puguang Biotechnology Co., Ltd., also known as Poclight Biotechnology, is a developer and manufacturer operating in the in-vitro diagnostics (IVD) market, founded in 2019 and headquartered in Nanjing, China. The company is venture capital-backed, having raised a total of $23.7M. A significant funding round in July 2022 raised $15 million, co-led by Huatai Zijin Investment and Nanjing XinGong Investment Group, among other participants.
Poclight Biotechnology focuses on providing point-of-care testing (POCT) solutions for both human and veterinary medicine. The business model revolves around the development, production, and sale of diagnostic equipment and the accompanying reagents. Its client base includes hospitals, clinics, and laboratories. The company operates from a 5,000 square meter R&D and production site, which includes extensive GMP workshops. Poclight's core technology is a patented platform called "Chemiluminescence Resonance Energy Transfer" (CRET), which it describes as a fifth-generation chemiluminescence technology. This technology forms the basis of its homogeneous chemiluminescence immunoassay products.
The company's flagship product is the Poclight C5000, a semi-automated chemiluminescence immunoassay analyzer. A key feature of the C5000 system is its use of lyophilized (freeze-dried) reagent beads, which eliminates the need for cold chain transportation and storage, a significant logistical and cost advantage. The analyzer is compact, with a footprint the size of an A4 sheet, and is designed to deliver quantitative results for over 35 biomarkers in 3-15 minutes. It can analyze serum, plasma, and whole blood samples simultaneously across seven independent channels. The test menu covers a wide range of applications, including cardiac markers, inflammation, thyroid function, metabolism, diabetes, and hormone panels for human diagnostics, as well as specific tests for veterinary use like canine C-Reactive Protein (cCRP) and feline pancreatitis-specific lipase (fPL).
Source: Dealroom company dataNews
Open roles
Nanjing Puguang Biotechnology in the Nanjing City ecosystem
The Nanjing Puguang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Huatai Zijin Investment
Series A2 investors entered at this stage
- ACAnfeng Venture Capital
- WIWenzhou Investment
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanjing Puguang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanjing Puguang Biotechnology on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


